varicella virus vaccine

The varicella virus vaccine is a live attenuated vaccine that protects against infection with the varicella-zoster virus, which causes chickenpox. The primary mechanism of action is to stimulate an immune response by introducing a weakened form of the live virus, leading to immunity without causing disease in healthy individuals. The standard regimen consists of two doses administered subcutaneously—first at 12–15 months and second at 4–6 years—with catch-up vaccination for older children and adults who lack immunity. The main indication is prevention of chickenpox (varicella) in children and adults; it also indirectly reduces the risk of shingles (herpes zoster) later in life by priming immune memory against the virus. Major brand names include Varivax (Merck), Varilrix (GSK), and Proquad (a combination MMRV product). Not all countries recommend routine use due to cost or epidemiological considerations[1][2][4][5][6].

Brand names

VarivaxVarilrixProquad

Other names

chickenpox vaccinevaricella zoster vaccine (live/attenuated)varicella vaccine